# Contact CJC-1295 Pharmacy

> Contact CJC-1295 Pharmacy — editorial correspondence about the CJC-1295 dossier. We do not provide medical advice, do not refer to compounders or clinics, and do not sell any product.

_Editorial correspondence only — corrections to citations, requests for additional literature, notes on the dossier method. No clinical or commercial inquiries._

## Editorial correspondence

CJC-1295 Pharmacy is reachable by email for editorial correspondence: corrections to citations, requests that we cover an additional published study, observations about the dossier method, or notes from peer researchers who want to flag a paper we have missed. We respond when we can. We do not provide medical advice and do not respond to inquiries about dose, protocol, or product purchase.

We do not refer to compounding pharmacies. We do not refer to clinics, telehealth services, or peptide vendors. We do not maintain a referral relationship with any entity in the commercial peptide ecosystem. The dossier is editorial and independent — its only relationship is to the published literature.

## What we cannot do

We cannot recommend a dose. We cannot prescribe. We cannot fill a script. The 'pharmacy' in our domain name is editorial framing, not a service offering — the position the publisher occupies relative to the compounding-pharmacy literature, not a commercial pharmacy.

For clinical questions about growth-hormone-axis therapy, the appropriate resource is a licensed endocrinologist with access to the patient's full medical history. For regulatory questions about the FDA 503A compounding status of CJC-1295, the FDA Pharmacy Compounding Advisory Committee briefing materials and the September 2024 Category 2 action are the canonical public-record sources [14][17]. For WADA-prohibited-list questions, the 2026 list document on the WADA website is the source of record [15].

## Contact form

A simple editorial contact form is provided below. Required fields: name, email, message. We read every submission; we cannot promise a reply to every one. Please indicate in the subject line whether your message is a citation correction, a literature suggestion, or a method note.

## References

[14] U.S. Food and Drug Administration. FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting on peptide bulk drug substances. 2024. https://www.fda.gov/media/183819/download

[15] World Anti-Doping Agency. The Prohibited List — International Standard (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). WADA Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

[17] Lexology editorial. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review. 2024. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d

---

A compounding-pharmacy reading room for the CJC-1295 research record — Phase I evidence rendered in solid rules, gray-literature claims in dashed ones, no scripts filled on the premises.